[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Oriol Manuel\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":77},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,51],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100636803","phase-4-horus-cytomegalovirus-open-proof-of-concept-exploratory-trial-100636803",false,"NCT07570433","HORUS-Cytomegalovirus Open Proof-of-concept Exploratory Trial","HORUS-Cytomegalovirus Open Proof-of-concept Exploratory Trial (HORUS-COPE): An International Proof-of-concept Clinical Trial on Modulation of Immunosuppressive Regimen in Solid-organ Transplant Recipients With Cytomegalovirus Infection.","HORUS-COPE","Inclusion Criteria:\n\n* Clinically stable adult patients (aged 18 years or older) who have received a solid organ transplant (e.g., kidney, liver, heart, lung, pancreas) and developed clinically significant CMV infection as determined by positive CMV PCR.\n* On maintenance therapy of tacrolimus, MPA, +\u002F- steroids.\n* Informed consent signed.\n\nExclusion Criteria:\n\n* Active acute graft rejection or significant graft dysfunction requiring modification of the current immunosuppressive regimen, in the opinion of the investigator.\n* Receipt of more than 72 hours of antiviral therapy for CMV infection prior to enrolment, before randomization, including valganciclovir and\u002For IV ganciclovir therapy\n* Known intolerance or hypersensitivity to mTOR inhibitors or to any component of the everolimus formulation.\n* Any medical condition that constitutes a contraindication to everolimus use, as judged by the investigator.\n* Additional exclusion criteria for French sites:\n\n  * Patient not affiliated to the French social security system\n  * Patient under legal protection (guardianship, curatorship).","ALL","18 Years",{"count":20,"type":21},100,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","Cytomegalovirus (CMV) remains a significant cause of morbidity and mortality following organ transplantation.\n\nCell-mediated immunity plays a crucial role in controlling CMV replication after transplantation. Immune monitoring involves the use of immune biomarkers to dynamically estimate the risk of CMV replication. This approach allows for the individualization of preventive and therapeutic strategies, improving patient outcomes.\n\nThe HORUS-COPE trial is designed to assess the effect of immune modulation on CMV replication kinetics and to explore the performance of a selected immune signature during antiviral therapy for CMV infection to stratify patients based on their risk of not responding to immune modulation.",[27],"CMV Infection",[29,30,31,32,33,34,35,36,37],"solid organ transplantation","CMV","cytomegalovirus","immunosuppression","everolimus","mTORi","MPA","infection","immune signature","NOT_YET_RECRUITING","2026-04-29",{"date":41,"type":42},"2026-05-06","ACTUAL",{"date":44,"type":21},"2026-04",{"date":46,"type":21},"2028-03",{"name":48,"class":49},"Oriol Manuel","OTHER",4,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":22,"phases":61,"briefSummary":63,"conditions":64,"keywords":66,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},"100627059","phase-2-zoster-vaccine-to-enhance-protection-against-zoster-in-solid-organ-transplantation-100627059","NCT07443709","Zoster Vaccine to Enhance Protection Against Zoster in Solid-organ Transplantation","A Single-centre Open-label Parallel Two-arms Pilot Randomized Clinical Trial of a Booster Recombinant Zoster Vaccine in Solid-Organ Transplant Recipients","ZEST","Inclusion Criteria:\n\n* Aged ≥18 years\n* SOT recipient who has received two doses of the Shingrix® vaccine (primary vaccination).\n* At least 6 months after transplantation\n* At least 6 months after the completion of the Shingrix® primary vaccination series.\n* At least 8 weeks have elapsed since any treated episode of acute allograft rejection or At least 6 months if B-cell depleting antibodies (e.g. rituximab, alemtuzumab) was used as part of the treatment.\n* Signature of the written informed consent.\n\nExclusion Criteria:\n\n* Acute febrile illness or active infection at the time of enrolment, as determined by the investigator (patients can be enrolled in a later stage).\n* Known hypersensitivity to any component of RZV.\n* Willing to become pregnant",{"count":60,"type":21},75,[62],"PHASE2","Shingles is caused by the same virus that causes chickenpox. After someone has chickenpox, the virus stays in the body and can become active again later in life. This is called shingles.\n\nPeople who have received a solid organ transplant (such as a kidney, liver, or heart transplant) are 3 to 10 times more likely to get shingles than the general population. In transplant patients, shingles is often more severe. It can spread to other parts of the body and may cause long-lasting nerve pain. These problems can lower quality of life, increase doctor visits and hospital care, and may even affect how well the transplanted organ works.\n\nThe shingles vaccine called Shingrix® (recombinant zoster vaccine, RZV) works well in healthy adults and is generally safe for transplant patients. However, about 30% of transplant recipients still develop shingles even after receiving the recommended two doses. This may be because their immune system is weakened by the long-term medicines they take to prevent organ rejection.\n\nThe purpose of this clinical trial is to find out whether giving an extra (booster) dose of the shingles vaccine after transplant can improve the immune response in solid organ transplant recipients.\n\nThis study aims to answer the following questions:\n\n* How many participants have at least twice as many shingles antibodies (anti-gE antibodies) four weeks after receiving the booster compared to before the booster?\n* How strong and how long does the immune response last at 6 and 12 months?\n* Is the booster dose safe for transplant patients? In this study, researchers will compare two groups: One group will receive a booster dose of the shingles vaccine. The other group will not receive the booster. They will compare the groups to see differences in immune response, cases of shingles despite vaccination, and any side effects.\n\nParticipants in the study will:\n\n* Be randomly assigned (by chance) in a 2:1 ratio to either receive the booster or not.\n* Have blood samples taken at the first visit, and again at 1 month, 6 months, and 12 months to measure antibody levels and immune responses.\n* Be monitored for any possible side effects.\n* Have their medical records reviewed for health events such as side effects or organ rejection.",[65],"Zoster; Herpes",[67,68],"Solid Organ Transplant (SOT) Recipients","recombinant zoster vaccine","2026-02-24",{"date":71,"type":42},"2026-03-02",{"date":44,"type":21},{"date":74,"type":21},"2027-04",{"name":48,"class":49},1,""]